ERBB2 and neoplasm: Furthermore, we could identify a patient cohort with LM with a better prognosis, i.e. patients at younger age, better performance status, triple-positive tumor biology, low number of BM as well as patients receiving endocrine therapy (if HR + tumor biology), HER2-targeted therapy (if HER2+ tumor) or radiotherapy of the brain.